PXN and neoplasm: Thus, in this scenario, GSK-3 was acting as a tumor promoter and suppressing GSK-3 activity with inhibitors could reduce tumor aggressiveness by suppression of both the disassembly of paxillin and activation of FAK and RAC [37].